Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 21 of the 34 sources its claims cite were checked for support.

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

Open access

Abstract

BACKGROUND: Weight regain after weight loss is a major problem in the treatment of persons with obesity. METHODS: In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed. RESULTS: After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, -4.1 kg (95% confidence interval [CI], -7.8 to -0.4; P = 0.03); in the liraglutide group, -6.8 kg (95% CI, -10.4 to -3.1; P<0.001); and in the combination group, -9.5 kg (95% CI, -13.1 to -5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, -5.4 kg; 95% CI, -9.0 to -1.7; P = 0.004) but not liraglutide (-2.7 kg; 95% CI, -6.3 to 0.8; P = 0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (-1.7 percentage points; 95% CI, -3.2 to -0.2; P = 0.02) and the liraglutide group (-1.9 percentage points; 95% CI, -3.3 to -0.5; P = 0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group. CONCLUSIONS: A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone. (Funded by the Novo Nordisk Foundation and others; EudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716.).

Overview

CoChat Summary

## TL;DR

In this randomized, placebo-controlled trial of adults with obesity who first lost weight on an 8-week low-calorie diet, exercise plus liraglutide maintained weight loss better than either treatment alone. The combination also produced broader metabolic benefits, including improved body-fat percentage, glycated hemoglobin, insulin sensitivity, cardiorespiratory fitness, and physical functioning.

## Key findings

  • After the 8-week low-calorie diet, 195 participants had a mean body-weight decrease of 13.1 kg; these participants were randomized to 1 year of treatment.
  • At 1 year, compared with placebo, mean weight change differed by -4.1 kg with exercise, -6.8 kg with liraglutide, and -9.5 kg with the combination.
  • The combination reduced body-fat percentage by 3.9 percentage points, versus -1.7 percentage points compared with exercise and -1.9 percentage points compared with liraglutide; it was the only strategy associated with improvements in glycated hemoglobin, insulin sensitivity, and cardiorespiratory fitness.
  • Mean total weight loss from baseline to end of trial was 15.7% in the combination group, 10.9% with exercise, 13.4% with liraglutide, and 6.7% with placebo.

## Methods

  • Investigator-initiated, randomized, head-to-head, placebo-controlled trial at Hvidovre Hospital and the University of Copenhagen; participants were randomized in a 1:1:1:1 ratio after an 8-week 800-kcal/day low-calorie diet.
  • Sample: adults 18 to 65 years with obesity (BMI 32 to 43) and no diabetes; 215 started the diet and 195 (those losing at least 5% of baseline weight) were randomized.
  • Main analysis used an intention-to-treat repeated-measures linear regression model with time, group, sex, age group, and time-by-group interaction; prespecified supplementary analyses included per-protocol, adjustment for initial weight loss, and multiple imputation.

## Limitations

  • The paper states results may not be generalizable to older persons (>65 years), persons with BMI >43, patients with type 2 diabetes, or persons with low adherence to moderate-to-vigorous exercise or limited ability to exercise.
  • The authors note that some participants missed the week-52 assessment: 166 of 195 (85%) attended the primary endpoint visit.
  • Evident from the text: the trial was conducted in Denmark at two sites and in participants who first achieved at least 5% weight loss on a low-calorie diet, so applicability to broader obesity populations and to people unable to lose weight initially is not directly tested.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2028198

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

12 Valid · 1 Not valid · 3 Not checked · 76 Own results and interpretations

42 more claims · 2 with their cited sources checked

Create a free account to see all 92 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 31
  • Probably not a substantial claim. 21
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

41 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 35 references

Cited by

See all 536

Metadata

Authors
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., Jensen, J.-E. B., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S.
Affiliations
  • University of Copenhagen (DK)
  • From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital–Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) — all in Denmark.
  • Amager Hospital (DK)
Venue
New England Journal of Medicine
Published
2021-05-06
Volume
384
Issue
18
Pages
1719-1730
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3158123746
Cited by
536
References
35
Citations by year
2026: 140 · 2025: 137 · 2024: 86 · 2023: 78 · 2022: 71 · 2021: 23
FWCI
37.66
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
Funders
  • Helse Fonden
  • Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
  • Danish Diabetes Academy
  • Novo Nordisk Fonden (NNF15CC0018486, NNF16OC0019968)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
obesity, weight loss maintenance, weight regain, liraglutide, physical activity, hypocaloric diet, body fat percentage, GLP-1 receptor agonists, combination therapy, metabolic health
MeSH terms
Liraglutide, Adipose Tissue, Adult, Combined Modality Therapy, Exercise Therapy, Female, Humans, Male, Middle Aged, Obesity, Weight Loss, Anti-Obesity Agents, Caloric Restriction, Body Size

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. https://app.cochat.ai/papers/10.1056/nejmoa2028198
The paper
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., Jensen, J.-E. B., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S. (2021). Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2028198

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.